Presentations at the American College of Gastroenterology 2016 Annual Scientific Meeting highlighted promising therapies under development for nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. Dr. Violeta Popov of New York University Langone Medical Center said new endoscopic interventions for treating obesity may also boost outcomes in NASH and NAFLD.
Obese patients with type 2 diabetes had worse dyslipidemia, hyperinsulinemia and insulin resistance when they also had nonalcoholic steatohepatitis than those without NASH, according to a study in Diabetes Care. Researchers used a cohort of 154 obese patients with and without type 2 diabetes, NASH or nonalcoholic fatty liver disease and found an association between NASH and more dysfunctional and insulin resistant adipose tissue, as well as between insulin suppression of plasma free fatty acids and the severity of hepatic steatosis and steatohepatitis.
An analysis of data on 11,416 adults ages 20 to 74 showed men and older patients who regularly took aspirin had lower odds of developing nonalcoholic fatty liver disease. A similar link was not found in female and young aspirin users, researchers reported at the American College of Gastroenterology annual meeting.
According to Chinese researchers, data show patients with non-alcoholic fatty liver disease had significantly lowered levels of serum potassium. They said insulin resistance and central-body obesity could be connected to low potassium and the development of NAFLD and called for research into whether addressing low levels of potassium could help prevent NAFLD.
U.S. pediatric researchers said metabolic syndrome may be linked to liver disease in obese teenage boys but not in girls. Their study found a strong association between metabolic syndrome and elevated levels of alanine aminotransferase, a liver enzyme that is a marker of nonalcoholic fatty liver disease.